1. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: From translational research to treatment;Tepper;Headache,2018
2. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: Results from a double-blind, randomized, placebo-controlled trial, Study 301. Poster PS123LB 2018
3. Efficacy, safety, and tolerability of rimegepant 75 mg, an oral CGRP receptor antagonist, for the acute treatment of migraine: Results from a double-blind, randomized, placebo-controlled trial, Study 302. Poster IOR-02LB 2018
4. A phase 1 study to evaluate the bioequivalence of oral tablet and orally dissolving tablet formulations of rimegepant in healthy adult subjects under fasting conditions. Poster PF116LB 2018
5. Rimegepant and BHV-3500, small molecule CGRP receptor antagonists, exhibit no active vasoconstrictive properties in ex vivo human coronary or cerebral arteries. Poster LBOR-08 2018